Echo findings in heart failure patients with preserved or mildly reduced ejection fraction treated with an atrial shunt shed light on why only certain patients respond to therapy.
An updated expert consensus statement on catheter and surgical ablation of atrial fibrillation offered practical advice on various new tools in the field.
The Class I recall stems from reports of increased resistance in the guidewire handle and chamber during use, which could cause injury to the blood vessel walls.
Edwards Lifesciences received approval for its Evoque tricuspid valve replacement system, the first transcatheter therapy approved in the US for tricuspid regurgitation.
The Amulet and Watchman FLX devices for left atrial appendage closure produced equivalent results, with about half of patients having residual patency of the appendage at 13 months, a study shows.